关键词: lncRNA-PCAT6, miR-16, 胶质瘤, 预后

Abstract: Objective To investigate the expression of lncRNA PCAT6 and miR-16 in human glioma and their relationship with clinicopathological features and prognosis.Methods 94 glioma tissues frozen in the pathology department of Xi’an First Hospital from June 2016 to June 2018 were selected as the study group,and 100 brain tissues removed during craniocerebral injury decompression in the same period were selected as the control group.The relative expression levels of lncRNA PCAT6 and miR-16 were measured by real-time fluorescence quantitative PCR(qRT-PCR),and the patients were followed up for 3 years.Results The expression of lncRNA-PCAT6 in glioma tissue of the study group was significantly higher than that of the control group(P<0.05),while the expression of miR-16 was significantly lower than that of the control group(P<0.05).The proportion of patients with high WHO grade in lncRNA-PCAT6 high expression group and miR-16 low expression group was significantly higher than that in lncRNA-PCAT6 low expression group and miR-16 high expression group(P<0.05).The 3-year overall survival rate in lncRNA-PCAT6 high expression group and miR-16 low expression group was significantly lower than that in lncRNA-PCAT6 low expression group and miR-16 high expression group(P<0.05).High WHO grade,lncRNA-PCAT6 high expression and miR-16 low expression were independent risk factors affecting the poor prognosis of glioma patients(P<0.05).Conclusion lncRNA-PCAT6 is highly expressed in gliomas and miR-16 is low expressed in gliomas.Its expression level is significantly correlated with the prognosis of patients.

Key words: lncRNA-PCAT6；miR-16；Glioma, prognosis